The highly homologous sequences shared by Tau and MAP2 that exhibit similar neurotoxicity have different fates in the process of NFT formation in the AD brain, as shown by the newly raised MAP2 carboxyl-terminal site-specific antibodies used in this study. The gene discussed is MAP2; the disease is Alzheimer disease.